Clinical Trial Update: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial at Fox Chase Cancer Center tests the combination of pacritinib and talazoparib in myeloproliferative neoplasms unresponsive to JAK2 inh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Myelomonocytic Leukemia
• Polycythemia Vera
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Pacritinib (pacritinib)
• Talazoparib (talazoparib)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 | Status: RECRUITING